Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187563 | 0.80 | IDO1 (0.52) | IDO1PNMTTAAR1PKMLMNA | |
| SCHEMBL23881742 | 0.79 | TAAR1 (0.54) | IDO1PNMTTAAR1PKMNPC1 | |
| SCHEMBL1437844 | 0.78 | PNMT (0.39) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| SCHEMBL6295032 | 0.75 | TAAR1 (0.44) | PNMTTAAR1LMNATSHRNPC1 | |
| SCHEMBL1821 | 0.74 | — | — | |
| SCHEMBL29413238 | 0.74 | — | — | |
| SCHEMBL29519238 | 0.73 | IDO1 (0.62) | IDO1PNMTTAAR1PKMLMNA | |
| SCHEMBL672407 | 0.73 | IDO1 (0.62) | IDO1PNMTTAAR1PKMLMNA | |
| SCHEMBL6740216 | 0.73 | TAAR1 (0.71) | IDO1PNMTTAAR1PKMLMNA | |
| SCHEMBL376871 | 0.72 | TAAR1 (0.50) | IDO1TAAR1LMNATSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559466-B2 | Process for preparation of intermediates | UPL LTD (IN) | 2026-02-24 | — | — | US | disclosed |
| EP-4385329-A2 | IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES | UPL Ltd (IN) | 2024-06-19 | — | — | EP | disclosed |
| CN-112399967-A | Improved process for the preparation of intermediates | UPL有限公司 | 2021-02-23 | — | — | CN | disclosed |
| US-20200399236-A1 | IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES | UPL LTD (IN) | 2020-12-24 | — | — | US | disclosed |
| CN-101970391-B | Process for preparing pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN | 2013-09-18 | — | — | CN | disclosed |
| US-8394993-B2 | Process for the preparation of pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-03-12 | — | — | US | disclosed |
| EP-2231575-B1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2011-06-22 | — | — | EP | disclosed |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-10-28 | — | — | US | disclosed |
| CN-1878762-B | Morpholine derivatives as norepinephrine reuptake inhibitors | LILLY CO ELI | 2010-10-27 | — | — | CN | disclosed |
| EP-2231575-A2 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2010-09-29 | — | — | EP | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| US-6951942-B2 | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LABORATORIES (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6506766-B1 | A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid | ABBOTT LABORATORIES | 2003-01-14 | — | — | US | disclosed |
| EP-1053239-B1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LAB (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1053239-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999041256-A1 | GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559466-B2 | Process for preparation of intermediates | CBR1, POR, CYP2E1 | IDO1 321/4885PNMT 445/4885TAAR1 500/4885 |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | PF4, F2, F3 | IDO1 3637/4885PNMT 3968/4885TAAR1 3966/4885 |
| US-20200399236-A1 | IMPROVED PROCESS FOR PREPARATION OF INTERMEDIATES | OGDH, OXGR1, POR | IDO1 528/4885PNMT 465/4885TAAR1 721/4885 |
| US-20030073703-A1 | Glucocortiocoid-selective antinflammatory agents | NR3C1, GPR119, MC2R | IDO1 564/4885PNMT 4055/4885TAAR1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.